NMRA
Neumora Therapeutics Inc.

1,135
Mkt Cap
$354.23M
Volume
2.04M
52W High
$3.25
52W Low
$0.611
PE Ratio
-1.45
NMRA Fundamentals
Price
$2.39
Prev Close
$2.12
Open
$2.11
50D MA
$2.02
Beta
1.85
Avg. Volume
2.4M
EPS (Annual)
-$1.53
P/B
2.60
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts
Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) has earned an average recommendation of "Hold" from the eleven research firms that are presently covering the firm, MarketBeat Ratings...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Short Interest in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Drops By 20.2%
Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totaling...
MarketBeat·8d ago
News Placeholder
FY2030 Earnings Estimate for NMRA Issued By HC Wainwright
Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Neumora Therapeutics in a report...
MarketBeat·13d ago
News Placeholder
Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Leerink Partnrs
Leerink Partnrs raised shares of Neumora Therapeutics to a "strong-buy" rating in a research note on Monday...
MarketBeat·28d ago
News Placeholder
Leerink Partners Begins Coverage on Neumora Therapeutics (NASDAQ:NMRA)
Leerink Partners initiated coverage on shares of Neumora Therapeutics in a research note on Monday. They issued an "outperform" rating and a $8.00 price objective for the company...
MarketBeat·28d ago
News Placeholder
Neumora Therapeutics touts Phase 1B NMRA-511 gains in Alzheimer's agitation, eyes higher doses
Neumora Therapeutics (NASDAQ:NMRA) reported top-line results from a Phase IB signal-seeking study of NMRA-511 in agitation associated with dementia due to Alzheimer's disease, with management...
MarketBeat·1mo ago
News Placeholder
Neumora Therapeutics (NASDAQ:NMRA) Price Target Raised to $3.00 at Stifel Nicolaus
Stifel Nicolaus lifted their price objective on Neumora Therapeutics from $2.00 to $3.00 and gave the company a "hold" rating in a research note on Monday...
MarketBeat·3mo ago
News Placeholder
Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 114,703 Shares
Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) insider Daljit Singh Aurora sold 114,703 shares of Neumora Therapeutics stock in a transaction on Tuesday, November 11th. The stock was sold...
MarketBeat·3mo ago
News Placeholder
Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 114,703 Shares of Stock
Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) insider Daljit Singh Aurora sold 114,703 shares of the stock in a transaction on Tuesday, November 11th. The shares were sold at an average...
MarketBeat·3mo ago
News Placeholder
HC Wainwright Has Optimistic Outlook of NMRA FY2025 Earnings
Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Stock analysts at HC Wainwright raised their FY2025 earnings per share estimates for Neumora Therapeutics in a report released on Sunday...
MarketBeat·3mo ago
<
1
2
...
>

Latest NMRA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.